Department of Obstetrics and Gynaecology, British Columbia Research Institute for Children's and Women's Health, University of British Columbia, Vancouver, British Columbia, Canada.
J Cardiovasc Med (Hagerstown). 2010 Jan;11(1):1-6. doi: 10.2459/JCM.0b013e32832e0af3.
Atherosclerosis is a complex disease process in which genetic, lipid, cellular and immunological factors combine to determine the location, severity and timing of lesion development and clinical events. It has been demonstrated, however, that inflammation governs atherosclerosis during the course of development of atherosclerosis. It has also been demonstrated that regulation of the inflammatory reaction (e.g. statins) is effective in decreasing the cardiovascular events and improving the prognosis of atherosclerotic diseases. Other anti-atherosclerosis agents introduced in this study are adiponectin, testosterone, defibrase, angiotensin-converting enzyme inhibitors, dextromethorphan, paeonol, 15-lipoxygenase inhibitors, curcumin, interferon-beta, quercetin, AGI-1067, peroxisome proliferator-activated receptor gamma ligands and garlic. Some antiplatelet drugs described here are aspirin, clopidogrel and glycoprotein IIb/IIIa receptor antagonist. The mechanism of action of these agents is depicted. A new way of targeting anti-atherosclerosis and antiplatelet drugs to atherosclerosis areas is introduced. The author uses an antioxidized low-density lipoprotein antibody that is also conjugated to a mixture of anti-atherosclerosis agents or antiplatelet drugs to target these agents specifically to the atherosclerosis area. With this kind of targeting, we can use a much higher dose of anti-atherosclerosis agents or antiplatelet drugs and have much fewer side effects.
动脉粥样硬化是一个复杂的疾病过程，其中遗传、脂质、细胞和免疫因素结合起来决定病变发展和临床事件的位置、严重程度和时间。然而，已经证明炎症在动脉粥样硬化的发展过程中控制着动脉粥样硬化。也已经证明，调节炎症反应（例如他汀类药物）可以有效减少心血管事件并改善动脉粥样硬化疾病的预后。本研究中介绍的其他抗动脉粥样硬化药物包括脂联素、睾酮、降纤酶、血管紧张素转换酶抑制剂、右美沙芬、丹皮酚、15-脂氧合酶抑制剂、姜黄素、干扰素-β、槲皮素、AGI-1067、过氧化物酶体增殖物激活受体γ配体和大蒜。这里描述的一些抗血小板药物是阿司匹林、氯吡格雷和糖蛋白 IIb/IIIa 受体拮抗剂。这些药物的作用机制如图所示。本文提出了一种将抗动脉粥样硬化和抗血小板药物靶向动脉粥样硬化部位的新方法。作者使用一种抗氧化低密度脂蛋白抗体，该抗体也与抗动脉粥样硬化药物或抗血小板药物的混合物偶联，将这些药物特异性靶向动脉粥样硬化部位。通过这种靶向，我们可以使用更高剂量的抗动脉粥样硬化药物或抗血小板药物，并且副作用更少。
